Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells
In: Cancer Letters, Jg. 311 (2011-12-08), Heft 2, S. 177-186
Online
academicJournal
Zugriff:
Abstract: We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression, an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished. Further, VPA pre-treatment enhanced androgen responsiveness of C-81, C4-2 and MDA PCa2b-AI cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells, and VPA pre-treatments increase androgen responsiveness. [Copyright &y& Elsevier]
| Titel: |
Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells
|
|---|---|
| Autor/in / Beteiligte Person: | Chou, Yu-Wei ; Chaturvedi, Nagendra K. ; Ouyang, Shougiang ; Lin, Fen-Fen ; Kaushik, Dharam ; Wang, Jue ; Kim, Isaac ; Lin, Ming-Fong |
| Link: | |
| Zeitschrift: | Cancer Letters, Jg. 311 (2011-12-08), Heft 2, S. 177-186 |
| Veröffentlichung: | 2011 |
| Medientyp: | academicJournal |
| ISSN: | 0304-3835 (print) |
| DOI: | 10.1016/j.canlet.2011.07.015 |
| Schlagwort: |
|
| Sonstiges: |
|